SARS‐CoV protease inhibitors design using virtual screening method from natural products libraries

B Liu, J Zhou - Journal of computational chemistry, 2005 - Wiley Online Library
Two natural products databases, the marine natural products database (MNPD) and the
traditional Chinese medicines database (TCMD), were used to find novel structures of potent …

In Silico Prediction of SARS Protease Inhibitors by Virtual High Throughput Screening

D Plewczynski, M Hoffmann… - Chemical biology & …, 2007 - Wiley Online Library
A structure‐based in silico virtual drug discovery procedure was assessed with severe acute
respiratory syndrome coronavirus main protease serving as a case study. First, potential …

Generation of predictive pharmacophore model for SARS-coronavirus main proteinase

XW Zhang, YL Yap, RM Altmeyer - European journal of medicinal chemistry, 2005 - Elsevier
Pharmacophore-based virtual screening is an effective, inexpensive and fast approach to
discovering useful starting points for drug discovery. In this study, we developed a …

Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points

S Sirois, DQ Wei, Q Du, KC Chou - Journal of chemical information …, 2004 - ACS Publications
Pharmacophore modeling can provide valuable insight into ligand− receptor interactions. It
can also be used in 3D (dimensional) database searching for potentially finding biologically …

Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation

TTH Nguyen, HJ Ryu, SH Lee, S Hwang… - Bioorganic & medicinal …, 2011 - Elsevier
Abstract The 3C-like protease (3CL pro) of severe acute respiratory syndrome associated
coronavirus (SARS-CoV) is vital for SARS-CoV replication and is a promising drug target …

Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase

Z Liu, C Huang, K Fan, P Wei, H Chen… - Journal of chemical …, 2005 - ACS Publications
The SARS coronavirus 3C-like proteinase is considered as a potential drug design target for
the treatment of severe acute respiratory syndrome (SARS). Owing to the lack of available …

Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies

KC Tsai, SY Chen, PH Liang, IL Lu… - Journal of medicinal …, 2006 - ACS Publications
The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) 3C-like
protease (3CLpro or Mpro) is an attractive target for the development of anti-SARS drugs …

Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor

H Konno, T Onuma, I Nitanai, M Wakabayashi… - Bioorganic & Medicinal …, 2017 - Elsevier
Synthesis and evaluation of new scaffold phenylisoserine derivatives connected with the
essential functional groups against SARS CoV 3CL protease are described. The …

Inhibitor design for SARS coronavirus main protease based on “distorted key theory”

QS Du, H Sun, KC Chou - Medicinal Chemistry, 2007 - ingentaconnect.com
In order to find effective peptide inhibitors against SARS CoV Mpro, an analysis was
performed for 11 oligopeptides that can be cleaved by the SARS coronavirus main protease …

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease

R Ramajayam, KP Tan, HG Liu, PH Liang - Bioorganic & medicinal …, 2010 - Elsevier
A series of 2-(benzylthio)-6-oxo-4-phenyl-1, 6-dihydropyrimidine as SARS-CoV 3CL
protease inhibitors were developed and their potency was evaluated by in vitro protease …